Ying, X., Tu, J., Wang, W., Li, X., Xu, C., & Ji, J. (2019). FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib. Onco Targets Ther.
Dyfyniad Arddull ChicagoYing, Xihui, Jianfei Tu, Wenxian Wang, Xingliang Li, Chunwei Xu, and Jiansong Ji. "FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib." Onco Targets Ther 2019.
Dyfyniad MLAYing, Xihui, et al. "FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib." Onco Targets Ther 2019.
Rhybudd: Mae'n bosib nad yw'r dyfyniadau hyn bob amser yn 100% cywir.